Payment overview · 2025
General Payments
$1,604.08
62 reported records · 12 companies
Healthcare provider profile · identity verified
Nathan Bining, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LIVONIA, MI · NPI 1538102165
Verified facts
What the public records show
CMS Open Payments records show Nathan Bining, MD received $1,604.08 in general payments during 2025 across 62 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $368.30 | 23.0% | 22 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $329.63 | 20.6% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $309.10 | 19.3% | 10 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $175.60 | 10.9% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.00 | 7.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $95.14 | 5.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $79.11 | 4.9% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $58.70 | 3.7% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $21.00 | 1.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.07 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.72 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.71 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,604.08 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $368.30 | 22 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $329.63 | 6 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $175.60 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $161.44 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $95.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $79.90 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $79.11 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $72.42 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.06 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $61.78 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 551 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 254 | 62 |
| Omeprazole | Omeprazole | 246 | 49 |
| Lisinopril | Lisinopril | 221 | 59 |
| Gabapentin | Gabapentin | 195 | 40 |
| Ibuprofen | Ibuprofen | 167 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 134 | 30 |
| Alprazolam | Alprazolam | 128 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 118 | 29 |
| Lovastatin | Lovastatin | 116 | 32 |
| Metformin Hcl | Metformin Hcl | 106 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 25 |
| Losartan Potassium | Losartan Potassium | 98 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 95 | 23 |
| Atenolol | Atenolol | 93 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 22 |
| Diazepam | Diazepam | 78 | 12 |
| Trazodone Hcl | Trazodone Hcl | 74 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 11 |
| Furosemide | Furosemide | 72 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 18 |
| Clonidine Hcl | Clonidine Hcl | 67 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 16 |
| Simvastatin | Simvastatin | 62 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 15 |
| Trulicity | Dulaglutide | 54 | 13 |
| Carvedilol | Carvedilol | 53 | 11 |
| Baclofen | Baclofen | 51 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 51 | suppressed |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Ozempic | Semaglutide | 49 | suppressed |
| Methocarbamol | Methocarbamol | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 47 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Prednisone | Prednisone | 42 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Famotidine | Famotidine | 39 | 11 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | 11 |
| Amoxicillin | Amoxicillin | 38 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Eliquis | Apixaban | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 24 |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Benzonatate | Benzonatate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,604.08 · 62 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, JOURNAVX, QUTENZA, REXULTI, SHINGRIX, SUBLOCADE, VRAYLAR, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error